Latest News
-
2 Multibagger Defence To Shield Your Money, Buy On April 24; Prabhudas Sets Target Prices, Stop Loss -
Rs 3.5/Share Dividend Declared: NBFC Declares 55.5% YoY Surge In PAT, Shares Up 87% In 1-Yr -
Rs 118/Share Dividend: Healthcare Stock Below Rs 400 Turned Ex-Dividend, Payout Soon; Buy For Rs 515 Target -
6,693% Returns: Below Rs 75, Pharma Penny Stock Ex-Dividend For Rs 40/Sh Payout After 9 Years; Do You Own? -
TCS Vs Infosys Vs Wipro Shares, ADRs, Upcoming Dividends: Which Mega IT Stocks To Buy After Q4 Results? -
SBI Card Launches 3 New Variants of Its Travel Credit Card ‘SBI Card MILES’ -
25% Dividend Record Date: Logistic Stock Nears 1-Year High And It Belongs To Mahindra; Motilal Neutral -
1:10 Split, 26 Dividends: Tata's 26-Year-Old Retail Stock In Focus, Q4, Dividend Ahead; Buy For Target Rs 4200 -
1:5 Split Soon: Rs 2,300 Defence Stock To Split Into Five Shares, Rs 400 Cr Fundraising Too; Hits 52-Week High -
Penny Stock Bags Back-To-Back Orders Worth Rs 500 Mn, 110 Mn; Shares Hit Upper Circuit
ISLL declares 83.10 pc growth in Q3 results
The company reported a net profit of Rs 24.61 crores for the Quarter ended 31st Dec 2010 registering a growth of 83 percent against the figure of Rs 13.45 crores for the Quarter ended 31st Dec 2009.
The turnover of the Company also rose by 42.9 percent.
Vice Chairman and the Managing director of the company stated, "Company's focus on high end export markets and on block buster molecule is yielding results as company is giving sustained revenues."
"Going forward company is looking at Quantum leap jump in its efforts to tap regulated markets which will improve the quality of our business and deliver strong numbers on a consistent basis," he added.
Ind-Swift Laboratories limited (ISLL) is a leading global player in Active Pharmaceutical Ingredients and Advanced intermediates.
OneIndia News
